Jiangsu Recbio Technology Co., Ltd. Class H (HK:2179) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Jiangsu Recbio Technology Co., Ltd. has successfully completed the enrollment for the Phase III clinical trial of its new shingles vaccine, REC610. This vaccine, designed for adults over 40, is being tested for its efficacy and safety at multiple centers in China. With the market currently dominated by GlaxoSmithKline’s Shingrix, there is significant demand for a domestic alternative like REC610.
For further insights into HK:2179 stock, check out TipRanks’ Stock Analysis page.